Table 3.

Network meta-analyses for PFS.

Atezolizumab + Bevacizumab
0.60 (0.45, 0.79)	Brivanib
0.65 (0.48, 0.87)	1.09 (0.87, 1.36)	Donafenib
0.52 (0.38, 0.70)	0.87 (0.69, 1.10)	0.80 (0.62, 1.03)	Erlotinib + Sorafenib
0.57 (0.35, 0.95)	0.96 (0.60, 1.53)	0.88 (0.55, 1.42)	1.10 (0.68, 1.79)	GEMOX + Sorafenib
0.89 (0.67, 1.19)	1.50 (1.22, 1.84)	1.38 (1.09, 1.74)	1.73 (1.36, 2.20)	1.56 (0.98, 2.49)	Lenvatinib
0.78 (0.58, 1.04)	1.30 (1.05, 1.62)	1.20 (0.94, 1.53)	1.50 (1.16, 1.93)	1.36 (0.84, 2.18)	0.87 (0.69, 1.09)	Linifanib
0.56 (0.42, 0.75)	0.94 (0.76, 1.17)	0.87 (0.68, 1.10)	1.08 (0.84, 1.39)	0.98 (0.61, 1.57)	0.63 (0.50, 0.78)	0.72 (0.57, 0.92)	Placebo
1.05 (0.77, 1.45)	1.77 (1.37, 2.27)	1.63 (1.23, 2.14)	2.04 (1.53, 2.70)	1.84 (1.13, 3.00)	1.18 (0.91, 1.53)	1.36 (1.04, 1.78)	1.88 (1.44, 2.45)	Sintilimab + Bevacizumab
0.59 (0.46, 0.75)	0.99 (0.86, 1.14)	0.91 (0.76, 1.09)	1.14 (0.94, 1.38)	1.03 (0.66, 1.61)	0.66 (0.57, 0.77)	0.76 (0.64, 0.90)	1.05 (0.89, 1.24)	0.56 (0.45, 0.69)	Sorafenib
0.63 (0.46, 0.88)	1.06 (0.82, 1.38)	0.98 (0.74, 1.29)	1.23 (0.92, 1.64)	1.11 (0.68, 1.82)	0.71 (0.54, 0.92)	0.82 (0.62, 1.08)	1.13 (0.86, 1.49)	0.60 (0.45, 0.82)	1.08 (0.86, 1.34)	Sorafenib + Doxorubicin
0.52 (0.40, 0.69)	0.88 (0.72, 1.06)	0.81 (0.64, 1.01)	1.01 (0.80, 1.27)	0.91 (0.57, 1.45)	0.58 (0.48, 0.72)	0.67 (0.54, 0.84)	0.93 (0.75, 1.15)	0.50 (0.39, 0.64)	0.88 (0.77, 1.01)	0.82 (0.64, 1.06)	Sunitinib
0.54 (0.35, 0.83)	0.91 (0.62, 1.33)	0.84 (0.56, 1.24)	1.05 (0.70, 1.57)	0.95 (0.54, 1.67)	0.61 (0.41, 0.89)	0.70 (0.47, 1.04)	0.96 (0.65, 1.43)	0.51 (0.34, 0.78)	0.92 (0.64, 1.31)	0.85 (0.56, 1.30)	1.04 (0.71, 1.52)	Tigatuzumab + Sorafenib

PFS, progression-free survival.